

Managing resources
for biomedical research



Biobanking in Biomedical Research

Part 6

The European Research Infrastructure for Biobanking and Biomolecular resources (BBMRI)


Kurt Zatloukal, Medical University of Graz, Austria

Siena, June 2009





Biobanks in Medical Research



NCI: Biological samples are #1 roadblock

OECD: Global Biological Resource Centre Network

WHO/IARC: Standards for biological resource centres

ESF: Science Policy Briefing: Need for integration

EU/ESFRI: Research infrastructure for Biobanks and
Biomolecular Resources (BBMRI)



The Next Big Questions

Why are we different?

- **Why remain some healthy until high age?**
- **Why do some develop certain diseases?**
- **Why do some respond to therapy?**
- **Why do some develop adverse drug reactions?**



- 1000 genomes project
- Cancer genome project
- Innovative Medicines Initiative
- Personalized medicine



Managing resources
for biomedical research



Progress in Sequencing Technologies



Sequencing of the human genome:

2001: Human Genome Project

10 years - 3 bio. USD



2008: Next generation sequencing

10 hrs - 50,000.- USD


Allows new research approaches

Shifts bottleneck to biological samples and data management



BBMRI
Biobanking and
Biomolecular
Resources Research
Infrastructure

The New Dimension in Life Sciences Research




The banner features a stylized map of Europe in shades of orange and yellow, overlaid with a network of white lines representing research infrastructures. The text is centered over this background.

EUROPEAN ROADMAP
FOR RESEARCH
INFRASTRUCTURES

Report 2006


The facility

A simple network diagram consisting of three grey squares connected by thin grey lines. One square is at the top, one is at the bottom left, and one is at the bottom right, forming a triangle with connecting lines.

A pan-European and broadly accessible network of existing and de novo biobanks and biomolecular resources. The infrastructure will include samples from patients and healthy persons, molecular genomic resources and bioinformatics tools to optimally exploit this resource for global biomedical research.

BBMRI
Biobanking and
Biomolecular
Resources Research
Infrastructure


Key Components of BBMRI



Managing resources for biomedical research




The pan-European Scale of BBMRI



Possible Legal Structure of BBMRI (ERIC)


Distributed hub and spoke structure



Managing resources for biomedical research



Organization (prep phase)





The Challenges

- Harmonized processes (evidence-based standards)
- Incentives for contributors
- Access rules
- Heterogenous European ethical and legal landscape
- Data protection in biobanking
- Sustainable funding





The Process

- Assessment of existing resources and technologies
- Concept for integration
- Prototype
- Infrastructure




The Questionnaire

- Evaluation of:
 - Available samples: type, quality, quantity
 - IT infrastructure, database, data protection
 - Governance structure
 - Access rules
 - Pertinent ELSI
 - Funding



Inventory

- Identify candidates for prototype and demonstration project
- Identify candidates for future members
- Basis for construction and operation plan





Inventory on Existing Disease-Oriented Biobanks


- BBMRI questionnaires have been developed jointly by all WPs and P³G
- were sent to European biobanks via the national coordinators
- Collection process is still ongoing
- Meanwhile returned:
 - 38 network questionnaires,
 - 185 core questionnaires,
 - 216 collection questionnaires and
 - 185 supplementary questionnaires
- Stored in a relational database system



Managing resources for biomedical research



Country	Network	Core	Collection	Supplements
Austria	2	12		2
Belgium		1		1
France	5	23	50	50
Germany	12	30	31	37
Greece		2	1	
Hungary	1	11	32	
Iceland	1	3		
Ireland		1		3
Israel	1	2		6
Italy	4	30	39	62
Portugal		1	34	
Romania		2		6
Spain	5	13	11	11
Sweden		1		
Switzerland	1	3		
The Netherlands	5	47	18	6
United Kingdom	1	3		1
TOTAL:	38	185	216	185



BBMRI
Biobanking and
Biomolecular
Resources Research
Infrastructure



Web-based Overview Catalogue

Erich Wichmann (WP3), Klaus Kuhn (WP5)

Basic requirements:

- Clearly presented key data of the individual biobanks (Background, objectives, number of samples etc.) with links to homepages
- Overview of existing samples, sorted by disease group
- Overview of biobanks that are part of the inventory
- Descriptive statistics of key questions (histograms etc.)
- Search function and possibility to sort
- Online entry of new biobanks with web-based forms and online update of data already stored in the database
- Comparison tables
- User administration





The Prototype

Aims


- The prototype should fulfil the role of proof-of principle for BBMRI. After being implemented under the final legal entity of BBMRI the prototype should be scaled up to the fully working infrastructure in the construction phase of BBMRI.
- Since the construction of a prototype of BBMRI is not part of the BBMRI PP, no funding from the BBMRI PP project is available and all activities along these lines have to be on a voluntary basis.
- All activities should be well coordinated with the BBMRI-PP and results should be made available for the construction of BBMRI





Key Features of the Prototype

- The prototype should reflect the distributed hub and spoke architecture of BBMRI.
- Procedures for efficient transnational exchange of samples and data that properly consider the applicable ethical and legal requirements should be established.
- The OECD best practice guidelines and the WHO/IARC guidelines for biological resource centres the should be considered.
- There should be only one BBMRI prototype. Consortia working on a prototype hub should well coordinate their activities with other consortia and the leader of the corresponding BBMRI workpackages.






Recommendations

It is recommended that biobanks participating in the prototype activity will address the following issues:

Evaluation of compatibility of:

- Sample & data quality
- Data formats (web interfaces, access)
- ELSI (applicable data protection legislation, requirements for REC approval, rules for access, etc.)

It should be explored whether the competent national authority for research infrastructures requests approval for participation in the prototype activity.





Some Expected Outcomes

- Standard Operating Procedures for collaboration including approved MTA, CDA, IC, assess rules
- Realisation of the quality criteria which are being developed in BBMRI
- Development of concept of BBMRI hubs including the options of a decentralized as well as a partially centralized repository
- To provide common access via the web site of the prototype

All established procedures should be suited to become integrated into the operational concept of BBMRI.





Prototype Hub for Disease-Oriented Biobanks

Partners


The BBMRI WP3 Prototype is open for disease-oriented biobanks. In the first stage the following partners will collaborate:

- BB-MUG: Medical University of Graz (Austria)
- PSI: The String of Pearls initiative (The Netherlands)
- BNADN: Spanish National DNA Bank (Spain)
- NetGerBB-Pilot: Network of German Biobanks – Pilot (Germany)
- Genethon: Genethon Network of Rare Diseases (France)

Managing resources for biomedical research




Distributed hub and spoke structure



Managing resources for biomedical research



Distributed hub and spoke structure



Managing resources for biomedical research



Table 1. Disease categories and topics of the involved biobanks.


DISEASES	BB-MUG	PSI	BN-ADN	Net-GerBB-Pilot	Gene-ton
Certain infectious and parasitic diseases	X			X	
Neoplasm	X	X	X	X	
Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism	X		X		
Endocrine, nutritional and metabolic diseases	X	X	X		
Mental and behavioural disorders		X	X	X	
Diseases of the nervous system	X	X	X	X	
Diseases of the eye and adnexa	X				
Diseases of the ear and mastoid process	X				
Diseases of the circulatory system	X	X	X	X	
Diseases of the respiratory system	X				
Diseases of the digestive system	X	X			
Diseases of the skin and subcutaneous tissue	X				
Diseases of the musculoskeletal system and connective tissue	X	X	X		
Diseases of genitourinary system	X	X			
Pregnancy, childbirth and the puerperium	X				
Certain conditions originating in the perinatal period	X				
Congenital malformations, deformations and chromosomal abnormalities	X				
Other	X				



BBMRI
Biobanking and
Biomolecular
Resources Research
Infrastructure



Different Levels of Data Processing





IT Requirements of BBMRI

- Great flexibility of data integration (communication adaptor)
- Ethical filter for different ethical and legal requirements of Member States and authorization of users
- Flexible query tools



The Adaptor Approach of BBMRI




- Define criteria
 - Which samples and data can be combined?
 - Evidence-based standards
- Develop tools
 - Data exchange
 - Sample intl. transfer

Managing resources for biomedical research



BBMRI IT-Architecture




BBMRI
Biobanking and
Biomolecular
Resources Research
Infrastructure



Involvement of the Biobanking Community


- ESF workshop, Amsterdam Dec. 06
- Establishment of FIBO, Paris, Dec. 06
- Stakeholder meeting Vienna, Feb. 07
- Presentation at EU Parliament , May 08
- Joint workshop DG Research, BBMRI, PHOEBE; Brussels, November 08
- Joint conference, Brussels, March 09
- Secretariat for OECD GBRCN, Mid 09





Involvement of Patients


- 1st Stakeholder meeting: Brussels, March 20th 09 (Chair: M. Griffith)
 - European Cancer Coalition (H. Sundseth)
 - Heart EU (M. Livingston)
 - Europ. Fed. of Crohn's and Ulcerative Colitis Associations (R. Mitchell)
 - EURORDIS (V. Bottarelli)
 - Internatl. Alliance of Patients' Organizations (S. McMahon)
 - Europ. Genetic Alliance Network (A. Kent)
- 2nd Stakeholder meeting: Brussels, September 16th 09






Involvement of Industry

- Specific issues
 - QA/QC
 - Access
 - Financing
- Projects
- Strategic issues
 - Long-term strategy for PPP (EFIPA, EDMA)
 - Joint analyses centers
 - Biomarker centers
 - Biobanking service





Access by the Industry




Problem if no scientific collaboration is possible since cost recovery is no reasonable incentive for contributors

Managing resources
for biomedical research



A New Model of PPP for Efficient Access of Industry






Analysis Centers

- Specifications defined together with industry
- Industry participates in QM
- Participation in ring trials
- Certification
- Projects performed like CRO
- Financing by using EIB loans and structural funds



Expected Impact of BBMRI

- BBMRI should provide a pan-European framework to foster excellence in biomedical research
 - Better projects, faster, cheaper
- Access to high quality resources, technologies, services, education and training
- Partner for academia and industry
 - SMEs: Strategic partner, customer
 - Pharma: Biomarker and drug development
- Incubator for regional development
 - Start-up packages





Opportunities for Regional Development

- Biological resources are the essential raw material for future health-related economies
- Biological resource centers may act as nucleus for the establishment of biotech and pharma clusters
- Opportunities for joint-ventures with industry
- Co-financing by structural funds and EIB loans



BBMRI and Publics


- Socio-economic impact study
(impact on research, industry, health care)
- Public perception (focus groups and Eurobarometer)
- Coordinated communication strategy of all BMS research infrastructures (joint task force)
- White paper for European Parliament




Managing resources
for biomedical research



1st Update of the ESFRI Roadmap



Synergies of BMS Research Infrastructures





How to Capitalize?

- Health-related economies are the potential next driver of global economy
- ESFRI BMS infrastructures together generate an enormous momentum and unique opportunity for European science, industry and society
- Value generating chain without gaps
- Implementation of the ERA in the life sciences
- Co-ordinated communication strategy





Communication Strategy: Content

- Expected impact of European BMS RIs on science, industry and society
 - Major impact on European life sciences, health care and economy
 - Unique opportunity for Europe
 - Implementation of ERA concept
 - Public curiosity about the secrets of the living world





Communication Strategy: Process



The BBMRI Team: WP Leaders and Chairs

Coordination/Executive Mgmt.	K. Zatloukal, AT; E. Vuorio, FI M. Yuille, UK; M Pasterk, FR
Population-based Biobanks:	L. Peltonen, FI/UK; A. Metspalu, EE
Disease-oriented Biobanks:	E. Wichmann, GER, T Meitinger, GER
Biomolecular Resources:	U. Landegren, SE; M. Taussig, UK
Databases & Biocomputing:	J-E Litton, SE
Ethical, Legal and Societal Issues:	A. Cambon-Thomsen, FR
Funding and Financing:	G. Dagher, FR; J. Ridder, NL C. Brechot, FR;
Governance Council Chair:	L. Peltonen, FI
Advisory Board Chair:	G-J van Ommen, NL
Coordination Board Chair:	K. Zatloukal, AT
Stakeholder Forum Chair:	M. Griffith, IR

50 Participants (6 Ministries, 18 Funding Organizations)

183 Associated Organizations 28 Countries

Managing resources for biomedical research



Further information

Kurt Zatloukal, M.D.
Institute of Pathology
Medical University of Graz
Auenbruggerplatz 25
A-8036 Graz
Austria

Tel: +43 316 380 4404
E-mail: kurt.zatloukal@meduni-graz.at

www.bbmri.eu

M. Yuille et al. *Briefing in Bioinformatics* 9: 14-24 (2008)